Evidence map›Paper›PMID 41410801›Full record

ArticleHuman cell2025

Generation and characterization of early stage oral cancer cell line of buccal mucosa of Indian origin.

Akhila George, Sudhir Nair, Kumar Prabhash, Sayujata Thakur, Poonam Gera, Arjun Singh, Pankaj Chaturvedi, Swapnil Rane, Trupti Pradhan, Subrata Sen and 6 more

Abstract read
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akhila GeorgeKode Lab, Tumor Immunology and Immunotherapy (TII) Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.ORCID http://orcid.org/0009-0008-5953-4433
Sudhir NairHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0003-4977-3779
Kumar PrabhashHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0001-8858-5004
Sayujata ThakurKode Lab, Tumor Immunology and Immunotherapy (TII) Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.ORCID http://orcid.org/0009-0009-4128-5640
Poonam GeraBiorepository Facility, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Arjun SinghHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0002-8119-8439
Pankaj ChaturvediHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0002-3520-1342
Swapnil RaneHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0002-5374-3903
Trupti PradhanKode Lab, Tumor Immunology and Immunotherapy (TII) Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.ORCID http://orcid.org/0000-0001-5491-2070
Subrata SenAnti-Cancer Drug Screening Facility (ACDSF), ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.ORCID http://orcid.org/0009-0004-1562-8746
Madan BarkumeAnti-Cancer Drug Screening Facility (ACDSF), ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Dhanlaxmi ShettyHomi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, 400094, India.ORCID http://orcid.org/0000-0003-2083-3176
Kruti ChaubalDepartment of Cancer Cytogenetics, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Arpita GhoshEurofins Genomics India Pvt. Ltd, Bengaluru, Karnataka, India.
Sanjeev KamteEurofins Genomics India Pvt. Ltd, Bengaluru, Karnataka, India.
Jyoti Anand KodeKode Lab, Tumor Immunology and Immunotherapy (TII) Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India. jkode@actrec.gov.in.ORCID http://orcid.org/0000-0001-6907-2449

Funding

ANRF SPG/2021/004734
6 · The paper itself

Abstract

Being topmost cancer in India, oral cancer management warrants discovery of novel biomarkers, treatment strategies, and targets to help with early diagnosis, treatment, and recovery. To have a continuous supply of cells, the study was aimed at generation and characterization of established cell line from buccal mucosa (BM) tumors from patients of Indian origin which can be developed as a pre-clinical tool for biomedical application. Surgically resected tumor tissue from histo-pathologically confirmed oral cancer were processed for explant culture. TBM-02 cell line was passaged and characterized for morphology and function. Further, the cell line was silenced for inflammasome pathway gene NLRP3 to evaluate its linkage with oral cancer tumorigenesis. TBM-02, successfully established from BM, was maintained up to 100 passages, exhibited epithelioid morphology, high EpCam expression and triploid ploidy with chromosomal aberrations. Novelty and human origin of TBM-02 was authenticated by Short Tandem Repeats profiling and comparison with DSMZ database. TBM-02 revealed tumorigenic potential in vitro and in vivo which was abrogated on silencing NLRP3. Increased expression of NLRP3, hallmark of chronic inflammation in TBM-02, was validated at protein and gene level and in xenograft. TBM-02 demonstrated migratory potential and was found to be a sensitive tool to study drug response. RNA sequencing demonstrated upregulation of oral cancer-associated genes and pathways. Thus, in current study, we have reported development of novel cell line from early-stage buccal mucosa cancer patient which has a strong potential to be developed and to be used as pre-clinical model for improving oral cancer management and therapeutics.

Indexed as

Mouth MucosaMouth NeoplasmsAnimalsCarcinogenesisCell Line, TumorHumansIndiaInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanCell lineCell xenograftChemosensitivityEarly-stage buccal mucosa cancerGeneration and establishment of cell lineNLRP3 therapeutic targetPre-clinical screening tool

Identifiers

PMID41410801
PMCPMC12714774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.